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METHODOLOGY
High-throughput malaria serosurveillance 
using a one-step multiplex bead assay
Eric Rogier1* , Lotus van den Hoogen2, Camelia Herman1,3, Kevin Gurrala4, Vena Joseph5, Gillian Stresman2, 
Jacquelin Presume6, Ithamare Romilus6, Gina Mondelus6, Tamara Elisme6, Ruth Ashton5, Michelle Chang1, 
Jean F. Lemoine7, Thomas Druetz5,8, Thomas P. Eisele5, Alexandre Existe6, Jacques Boncy6, Chris Drakeley2 
and Venkatachalam Udhayakumar1
Abstract 
Background: Serological data indicating the presence and level of antibodies against infectious disease antigens 
provides indicators of exposure and transmission patterns in a population. Laboratory testing for large-scale serosur-
veys is often hindered by time-consuming immunoassays that employ multiple tandem steps. Some nations have 
recently begun using malaria serosurveillance data to make inferences about the malaria exposure in their popula-
tions, and serosurveys have grown increasingly larger as more accurate estimates are desired. Presented here is a 
novel approach of antibody detection using bead-based immunoassay that involves incubating all assay reagents 
concurrently overnight.
Results: A serosurvey in was performed in Haiti in early 2017 with both sera (n = 712) and dried blood spots (DBS, 
n = 796) collected for the same participants. The  Luminex® multiplex bead-based assay (MBA) was used to detect 
total IgG against 8 malaria antigens: PfMSP1, PvMSP1, PmMSP1, PfCSP, PfAMA1, PfLSA1, PfGLURP-R0, PfHRP2. All sera 
and DBS samples were assayed by MBA using a standard immunoassay protocol with multiple steps, as well a proto-
col where sample and all reagents were incubated together overnight—termed here the OneStep assay. When com-
pared to a standard multi-step assay, this OneStep assay amplified the assay signal for IgG detection for all 8 malaria 
antigens. The greatest increases in assay signal were seen at the low- and mid-range IgG titers and were indicative of 
an enhancement in the analyte detection, not simply an increase in the background signal of the assay. Seropreva-
lence estimates were generally similar for this sample Haitian population for all antigens regardless of serum or DBS 
sample type or assay protocol used.
Conclusions: When using the MBA for IgG detection, overnight incubation for the test sample and all assay reagents 
greatly minimized hands-on time for laboratory staff. Enhanced IgG signal was observed with the OneStep assay for 
all 8 malaria antigens employed in this study, and seroprevalence estimates for this sample population were similar 
regardless of assay protocol used. This overnight incubation protocol has the potential to be deployed for large-scale 
malaria serosurveys for the high-throughput and timely collection of antibody data, particularly for malaria seropreva-
lence estimates.
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Background
Population-level detection of host antibodies has 
allowed estimates for transmission intensity [1–3], 
infection prevalence [4, 5], disease burden [6], and 
population immunity for vaccine preventable dis-
eases [7]. For greatest generalizability and epide-
miologic utility, serosurveys benefit from use of 
population-based probabilistic sampling methods and 
are strengthened when increased proportions of the 
population are sampled—inherently generating more 
statistical power and accurate estimates [8]. Serologi-
cal data are increasingly desired as supporting evi-
dence for verifying the interruption of transmission 
and infectious disease elimination from a population 
[7, 9], and serosurveys that include laboratory test-
ing for multiple diseases allow efficient monitoring of 
impact across programmes. Specifically for Plasmo-
dium spp. parasites, the presence of IgG antibodies 
against malaria antigens has been used as an indicator 
to generate point estimates for malaria transmission 
as well as to monitor changes in malaria burden in a 
population over time [10–12].
Antibody detection assays have evolved substantially 
over from detecting whether serum antibodies are pre-
sent at a titer defined as “positive”, to providing quanti-
tative estimates of antigen-specific antibodies present 
in a sample. Recently, multiplex bead-based immuno-
assays (MBAs) have further expanded antibody detec-
tion efforts, having the ability to assay for multiple 
targets simultaneously in the same well. This strategy 
has increased the feasibility of implementing integrated 
disease serosurveys [13, 14], with the additional benefit 
that the MBA has been shown to be more sensitive than 
ELISA for analyte detection of some targets [15–17]. As 
with the ELISA, current MBA protocols call for sequen-
tial steps of incubation with sample, incubation with a 
secondary (or detection) antibody, and incubation with 
a reporter that will provide a quantitative assay signal. 
Alternative protocols have also used secondary anti-
bodies directly linked to a reporter [16]. In performing 
these steps in this particular order, the researcher is able 
to ensure the signal above background generated by the 
immunoassay is a true signal reflective of the presence of 
the analyte. Here is presented a modification to the MBA 
that adapts the assay protocol to involve incubation of 
the sample and all reagents concurrently. This “OneStep” 
assay is formatted to include overnight incubation at 
room temperature, allowing for minimal hands-on time 
by laboratory staff, and obviating the need for washes 
between sequential incubation steps. To directly compare 
IgG both the antibody detection capacity of the standard 
and OneStep MBA protocols and estimates that would be 
generated for an actual serosurvey, 8 antigens from three 
Plasmodium species (Plasmodium falciparum, Plasmo-
dium vivax, and Plasmodium malariae) were tested on a 
sample set of sera (n = 712) and dried blood spots (DBS, 
n = 796) collected from the same participants in a 2017 
serosurvey in Haiti.
Methods
Human subjects and blood samples
Laboratory staff did not have access to personal identi-
fiers. Study participants consented for a diagnostic test 
and blood sample collection that would assay for mark-
ers of malaria. The field survey received approval from 
the Haitian Ministry of Public Health and Population 
Bioethics Committee (Comité National de Bioéthique) 
(#1516-30), and the Institutional Review Boards (IRBs) 
of Tulane University (#794709), and the London School 
of Hygiene & Tropical Medicine (#10393). Current labo-
ratory activity was not considered to constitute engage-
ment in human subjects research by the CDC Center 
for Global Health Office of the Associate Director for 
Science (#2016-135a). Consent for children (< 18  years) 
was provided by a parent or guardian and children above 
6  years gave assent to participate. Individuals aged 16 
or 17, who were married, head of household or a parent 
were considered ‘mature minors’ and consented directly. 
Thumbprint consent or assent (countersigned by a wit-
ness) was used for illiterate participants. Individuals 
under 6  months of age or requiring immediate medical 
attention were excluded. A single finger-prick was per-
formed on consenting participants to collect capillary 
blood (Safe-T-Fill™ Capillary Blood Collection Systems: 
EDTA, RAM Scientific Inc.) for spotting of whole blood 
on filter paper (Whatman 903, GE Healthcare); remain-
ing blood stored at 4  °C for later serum fractionation. 
Study participants also had a malaria rapid diagnostic 
test (RDT, SD Bioline Malaria Antigen P.f.; 05FK50), and 
individuals with a positive RDT result received free treat-
ment as per the national policy in Haiti. Serum and dried 
blood spot (DBS) samples (n = 796 DBS with 712 paired 
serum) were collected in April and May 2017.
At the Haitian national laboratory (Laboratoire 
National de Santé Publique, LNSP), blood remaining in 
the tube was centrifuged (5000g for 2 min) to fractionate 
and allow removal of serum. Blood dried on filter paper 
(dried blood spots, DBS) were eluted in Buffer B (PBS 
containing 0.5% BSA, 0.05% Tween 20, 0.02% sodium 
azide, 0.5% polyvinyl alcohol, 0.8% polyvinylpyrrolidone 
and 0.5% w/v Escherichia coli extract) by incubation 
overnight at 4 degrees. Whole blood elution from filter 
paper was done as to achieve a 1:50 whole blood dilution, 
which approximates a serum dilution of 1:100 with the 
assumption of 50% haematocrit in whole blood. Liquid 
serum was directly diluted 1:100 in Buffer B.
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Antigens and couplings
A summary of the 8 malaria antigens and the control 
antigen is displayed in Table 1. Recombinant Schistosoma 
japonicum glutathione-S-transferase (GST) protein cou-
pled to a bead was used as a generic protein non-binding 
control. The 19 kD fragment of the Plasmodium merozo-
ite surface protein 1 (MSP1) antigens for P. falciparum, 
P. vivax, and P. malariae have all been described previ-
ously [18]. The P. falciparum apical membrane anti-
gen 1 (AMA1), circumsporozoite protein (CSP), and 
liver stage antigen 1 (LSA1) antigens have also been 
described in previous studies from our group [19, 20]. 
The 19-amino acid glutamate-rich protein R0 (GLURP-
R0) fragment was synthesized as described previously 
[21], and the histidine-rich protein 2 (HRP2) Type A and 
Type B recombinant antigens were produced by Micro-
coat (Bernried am Starnberger See, Germany). For cou-
pling of the HRP2 antigen to the microspheres, a 1:1 
mixture was made of the Type A and Type B antigens so 
that equivalent amounts of these would be bound to the 
beads. All antigens were covalently linked to MagPlex 
(magnetic) microspheres (Luminex Corp., Austin, TX) as 
described previously [20]. Briefly, beads were pulse vor-
texed, transferred to a microcentrifuge tube and centri-
fuged for 1.5  min at 13,000g. Supernatant was removed 
and beads were washed with 0.1  M sodium phosphate, 
pH 6.2 (NaP). Beads were activated by suspending in NaP 
with 50  mg/mL of 1-ethyl-3-[3-dimethylaminopropyl]
carbodiimide hydrochloride (EDC) and 50 mg/mL sulfo-
NHS (sulfo N-hydroxysulfosuccinimide) and incubat-
ing with rotation for 20  min at room temperature (RT) 
protected from light. After wash with antigen-coupling 
buffer (4-morpholineethanesulfonic acid, MES; Sigma, 
St. Louis, MO), beads were suspended in antigen cou-
pling buffer with the appropriate concentration of anti-
gen (Table  1) and rotated for 2  h at RT protected from 
light. Beads were washed with PBS and suspended in 
PBS with 1% bovine serum albumin (BSA; Sigma) and 
incubated for 30 min at RT by rotation. Beads were then 
washed with storage buffer (PBS, 1% BSA, 0.02% sodium 
azide and 0.05% Tween-20) and suspended in storage 
buffer containing protease inhibitors (200  µg/mL Pefa-
bloc, 200 µg/ml EDTA, 1 µg/mL pepstatin A and 1 µg/mL 
leupeptin) and stored at 4 °C.
Bead‑based immunoassay protocols
The standard MBA protocol was performed as 
described previously [20], and illustrated in Fig.  1. 
Briefly, the standard assay was performed in flat bot-
tom BioPlex Pro 96 well plates (Bio-Rad, Hercules, CA) 
with washes between incubation steps used a handheld 
magnet (Luminex Corp). For wash steps, after addition 
of 100 µL wash buffer (PBS + 0.05% Tween-20, PBST) 
Table 1 Antigens used in the study multiplex panel
Antigen alias Organism Tag Source Antigen coupling concentration (per 
1.25 × 107 beads)
PfMSP1-19 Plasmodium falciparum GST Recombinant, CDC 30 µg in MES pH 5
PvMSP1-19 Plasmodium vivax GST Recombinant, CDC 30 µg in MES pH 5
PmMSP1-19 Plasmodium malariae GST Recombinant, CDC 30 µg in MES pH 5
PfCSP Plasmodium falciparum GST Peptide, CDC 30 µg in MES pH 5
PfAMA1 Plasmodium falciparum GST Recombinant, CDC 20 µg in MES pH 5
PfLSA1 Plasmodium falciparum – Peptide, CDC 60 µg in MES pH 5
PfGLURP-R0 Plasmodium falciparum – Peptide, CDC 30 µg in MES pH 5
PfHRP2 Plasmodium falciparum GST Recombinant, MicroCoat 25 µg in MES pH 5
glutathione-S-transferase Schistosoma japonicum – Recombinant, CDC 15 µg in MES pH 5
Fig. 1 Protocols for standard and OneStep MBA. Each step of assay 
protocols is outlined with incubation time between steps indicated 
in the arrows
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to each well, wash buffer was left in each well for one 
minute and magnet gently tapped to allow bead mag-
netization before inverting the plate to evacuate the 
wells of liquid. Beads (62,500  beads/antigen/plate) 
were suspended in Buffer A (PBS, 0.5% BSA, 0.05% 
Tween-20, 0.02%  NaN3) and 50  µL bead mastermix 
added to each well. Plates were washed two times with 
PBST and 50 µL of diluted sample (as described above) 
was added to each well and incubated with shaking 
at room temperature for 90  min. After 3 washes with 
PBST, beads were incubated with 50  µL biotinylated 
detection antibody mix consisting of: anti-human 
IgG (1:500, 9042-08, Southern Biotech, Birmingham, 
AL) and anti-human  IgG4 (1:625, 9200-08, South-
ern Biotech). Plates were incubated for 45  min and 
washed three times with PBST. 50  µL of streptavidin 
conjugated to phycoerythrin (PE) (1:200, S866, Inv-
itrogen, Waltham, MA) was added to detect bound 
secondary antibody. After a 30-min incubation, wells 
were washed three times with PBST and incubated in 
Buffer A for 30 min under light shaking to remove any 
loosely bound antibodies. Samples were resuspended 
in 100  µL PBS and shaken for 30  min to resuspend 
beads; fluorescence data were collected immediately 
on the MAGPIX with Bio-Plex Manager™ MP software 
(BioRad) with a target of 50 beads per region per well. 
Median fluorescence intensity (MFI) signal was gen-
erated for a minimum of 50  beads/region, and back-
ground MFI from wells incubated with Buffer B was 
subtracted from each sample to give a final value of 
MFI minus background (MFI-bg) for analysis.
The OneStep assay was performed (as illustrated in 
Fig.  1) with the same samples and reagents and con-
centrations used in the standard MBA protocol. In 
5  mL Buffer A, a bead mastermix was prepared with 
all regions included, and 50 µL bead mix was pipetted 
into a BioPlex Pro plate. Beads were washed 2× with 
100 µL PBST, and 50 µL reagent mix (in 5 mL Buffer A 
same dilution of reagents: 1:500 anti-human IgG, 1:625 
anti-human  IgG4, 1:200 streptavidin-PE) was added to 
all wells, then 50 µL samples (or controls) were added 
to the reagent mix in the appropriate wells. Plates were 
incubated overnight with gentle shaking at room tem-
perature and protected from light. The next morning 
(after ~ 16 h total incubation time), plates were washed 
3×, and beads resuspended with 100 µL PBS and read 
on the MAGPIX machine. MFI signal was generated 
for a target of 50  beads/region, and background MFI 
from wells incubated with Buffer B was subtracted 
from each sample to give a final value of MFI-bg. Com-
parison in incubation times was accomplished by using 
a dilution curve of hyperimmune sera pooled from 
different areas of the world endemic for P. falciparum 
malaria.
Statistical analysis
Statistical analyses were performed in SASv9.4 (SAS 
Institute, Cary, NC). Direct comparisons between MFI-
bg values using the two protocols were represented by 
k-nearest-neighbor-based local regression (LOESS) 
curves created through the SGPLOT procedure with 
cubic interpolation and a degree of 2, and 95% confidence 
limits. Log-transformed MFI-bg values were fit to a two-
component finite mixture model by the FMM procedure 
with normal distribution and maximum likelihood esti-
mation outputs for component means and variances.
Results
Serum and DBS samples from serosurvey assayed 
by both protocols
Scatterplots comparing the MFI-bg values for the same 
person’s serum and DBS sampled assayed with both 
protocols are shown for all antigens in Fig. 2 with non-
parametric LOESS curves and 95% confidence limits 
fit to the assay signal. In comparison to the y = x refer-
ence line which would indicate no change in assay signal 
between protocols, consistent increases in MFI-bg signal 
were observed for all antigens when using the OneStep 
protocol. As shown by the shape of each LOESS curve, 
the signal increase did not occur in a linear fashion over 
the range of IgG levels, and many of these curves mir-
ror the shape of an exponential cumulative distribution 
function (CDF) with a rapid increase that eventually 
plateaus. These signal increases were most pronounced 
at the lower and mid-range IgG signals, and the highest 
IgG assay signals equivalent for both assay protocols for 
the PfMSP1-19, PfAMA1, and PfGLURP-R0 antigens. 
For the other 5 antigens, even at the highest IgG levels, 
the MFI signal for the OneStep protocol was augmented 
when compared to the highest MFI signals for same sam-
ple as assayed with the standard protocol.
For the Haiti data, the 2-component finite mixture 
model (FMM) was used to estimate the antibody distri-
butions in two putative subpopulations for each anti-
gen: seronegative (the first, left-most component), and 
seropositive (the second, right-most component) [22, 
23]. This statistical approach was chosen as it could be 
applied to the MFI-bg data for all antigens used in this 
study, and the maximum likelihood estimation (MLE) 
parametric outputs could be directly compared between 
the two protocols and sample types. Visualizations of the 
2-component FMM plots for each antigen’s MFI-bg sig-
nals between the two protocols are shown in Fig.  3 for 
the four most immunogenic antigens and in Additional 
file  1 for the remaining antigens. The MLE outputs for 
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lognormal means and variance of these components are 
shown in Additional file  2. Figure  4 shows the change 
between protocols in the estimated means of the mod-
eled components for both sample types. Sample type 
did not appear to have a dramatic difference in the esti-
mated means for the first or second components, but 
the OneStep assay protocol increased these means for 
both sera and DBS data. Minor increases were seen 
with OneStep protocol for the first component; the sec-
ond component mean was substantially increased for 
most antigens (Fig.  4, Additional file  2). For both the 
sera and DBS data, a > 10-fold increase in the MFI-bg 
signal for the modelled mean of the second component 
was seen for PfMSP1-19 and PfAMA1, and a 1.5- to 8.2-
fold increase observed for the other six antigens. When 
observing the assay signal to the generic GST antigen 
(which served as a non-binding internal control for this 
multiplex panel), neither serum nor DBS MFI data were 
enhanced when employing the OneStep assay, and the 
LOESS curve comparing these assays largely follows the 
y = x line (Additional file 3). If varying only the OneStep 
assay incubation times, it was found that MFI-bg signal 
steadily increased with increased time of incubation, and 
was equivalent to the standard protocol at approximately 
30 to 90  min incubation time for the PfMSP1-19 and 
PfCSP antigens (Additional file 4).
Differences in seroprevalence estimates using different 
sample types and assay protocols
As malaria serological data is typically presented in 
a binary fashion [an individual is +/− for antibod-
ies against particular malaria antigen(s)], Table  2 shows 
the seroprevalence estimates that would be generated 
if applying the FMM approach to the Haiti data and 
defining a seropositivity signal threshold as described 
in Methods. A single antigen’s seroprevalence estimate 
was typically similar regardless of sample and proto-
col variations, and when comparing the average of four 
Fig. 2 Comparison of assay median fluorescence intensity minus background (MFI-bg) signal by both assay protocols and sample types. 
Relationship in MFI-bg values for the eight malaria antigens between two protocols and two sample types visualized as LOESS curves with cubic 
interpolation and 95% confidence limits in shading, with y = x reference as a hashed line
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Fig. 3 Fittings to two-component finite mixture models for antigen data collected by both assay protocols and sample types. Histograms are 
displayed for log-transformed MFI-bg values for the four most immunogenic malaria antigens as fit to a two-component finite mixture model. On 
each panel, estimates for lognormal mean and variance are displayed for the two components, and this information is included in Additional file 2. 
Plots for the remaining four antigens shown in Additional file 1
Fig. 4 Change in MFI-bg means for first and second components of finite mixture model. Estimated means for each component were compared 
between the two assay protocols and the two sample types for all eight malaria antigens. Outputs for modeled lognormal means and variances 
displayed in Additional file 2
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seroprevalence estimates (two sample types × two pro-
tocols). A notable exception to this was the estimate for 
PfAMA1 seropositivity for sera samples run with the 
OneStep protocol (10.1%) when compared to the other 
three estimates (27.8–34.6%).
Discussion
Serosurveillance is increasingly becoming an attractive 
and economical strategy for multiple disease-specific 
public health programs hoping to gather information 
within a population regarding pathogen exposure or 
vaccination coverage [9, 13, 23]. As the presence of IgG 
antibodies typically does not distinguish past from cur-
rent infection, serosurveillance provides information 
about exposure of a population to infectious agents over 
an extended period of time [24, 25]. We developed and 
evaluated a simplified IgG detection protocol by incu-
bating all reagents together overnight in the assay plate, 
thereby greatly minimizing hands-on time required by 
laboratory staff: termed here the OneStep protocol. The 
OneStep MBA protocol augmented the detection signal 
for all IgG responses measured against 8 Plasmodium 
antigens when compared to a standard step-wise MBA 
protocol. This was found to hold true for both sera and 
whole blood that had been eluted from filter paper (typi-
cally referred to as dried blood spots, DBS). Serological 
estimates from a serosurvey in Haiti of IgG prevalence in 
the study population were similar regardless of protocol 
or sample type, indicating that the novel OneStep proto-
col could generate malaria exposure prevalence estimates 
comparable to those generated using a standard protocol 
employing multiple incubation steps.
When comparing the OneStep to standard immunoas-
says, we found the greatest increases in signal detection 
capacity to be in the lower- to mid-range IgG levels. Aug-
mented assay signal may be due to the overall increased 
incubation time in the OneStep protocol (~ 16  h) that 
extends the period for specific antigen–antibody bind-
ing. Signal detection may also be boosted by the forma-
tion of IgG-reagent complexes when all immunoassay 
reagents are present simultaneously, and reagent associa-
tion is based on binding affinity and not tandem immu-
noassay steps. At the highest IgG concentrations, the 
data suggest that beads likely reach saturation of IgG-
antigen binding regardless of incubation time, and this 
may explain why MFI-bg signals for the PfMSP1-19, 
PfAMA1, and PfGLURP-R0 antigens generated by the 
two protocols tended to be more similar at the high-
est IgG concentrations. However, for the PvMSP1-19, 
PmMSP1-19, PfCSP, PfLSA1, and PfHRP2 antigens, the 
y-axis for maximum MFI signals was actually extended 
when using the OneStep protocol. Some stark examples 
of this were for the DBS data for PmMSP1-19 where 
max OneStep MFI-bg was 18,745 (compared to standard 
protocol max of 3842) and DBS data for PfHRP2 where 
max OneStep MFI-bg was 72,370 (compared to standard 
protocol max of 17,754). For IgG responses against many 
of the antigens, a noted limitation to the OneStep pro-
tocol was the loss of signal resolution at the higher IgG 
concentrations. When observing this shape of the non-
parametric LOESS curves applied to scatterplots, many 
of the curves mirrored an exponential CDF curve which 
rapidly rises and eventually plateaus. If the OneStep pro-
tocol (or really any immunoassay protocol) is being used, 
and quantitative data is desired for analytical purposes, 
it is important to consider the range(s) of antibody con-
centration that are expected, as different protocols will 
provide clearer resolution to specific ranges of antibody 
concentrations. Additionally, no “correct” or “incorrect” 
total time of incubation is required by this simultaneous 
incubation protocol, and different laboratories can adjust 
according to the type of information they wish to gather.
The increase in MBA signals from the OneStep pro-
tocol were indicative of improved detection of malaria 
Table 2 Comparison of  malaria seroprevalence estimates by  both  assay protocols and  sample types in  the  2017 Haiti 
survey
Antigen Serum Dried blood spot Average estimate
% seropositive (s.d.)
Standard (% positive) OneStep (% positive) Standard (% positive) OneStep (% positive)
PfMSP1-19 45.7 38.8 46.6 42.4 43.4 (3.5)
PvMSP1-19 5.8 8.9 7.0 7.9 7.4 (1.3)
PmMSP1-19 6.2 8.3 6.3 5.9 6.7 (1.1)
PfCSP 16.4 18.8 15.6 13.8 16.2 (2.1)
PfAMA1 27.8 10.1 27.9 34.6 25.1 (10.5)
PfLSA1 6.7 7.0 8.2 6.3 7.1 (0.82)
PfGLURP-R0 12.2 11.0 12.8 8.3 11.1 (2.4)
HRP2 11.4 13.1 8.7 13.1 11.6 (2.1)
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antigen-specific IgG. In applying the two-component 
FMM approach, the MLE estimates for the mean and 
variance for the first component (the putative back-
ground signal from running seronegative blood samples 
[22]) were generally similar between the two protocols 
with slight increases when using the OneStep method. 
This result indicates that the level of non-specific binding 
of blood proteins or assay reagents to the bead complex 
leading to background noise is largely unchanged when 
comparing the standard to OneStep protocols, and was 
further accentuated by the y = x concordance in assess-
ing assay signals to the non-binding GST control antigen. 
Importantly, the mean MFI-bg estimates for the second, 
‘seropositive’ FMM component were increased for all 8 
malaria antigens, showing the increase in the antigen-
specific IgG signal when utilizing the OneStep proce-
dure. The OneStep procedure results in less distribution 
overlap between the malaria seronegative and seroposi-
tive sub-populations, potentially minimizing Type 1 
(false positive) and Type 2 (false negative) misclassifica-
tion errors, and the width of the indeterminate region 
for demarcating seropositivity [26–28]. In reality, a true 
study population may have two, three, or more defined 
signal distributions indicating different categories of past 
exposure history, active infection status, malnutrition, 
and many other potential factors [23, 29].
Regardless of how many true components exist, hav-
ing a separation of other components away from the first 
(putative seronegative) component with reduced overlap 
in distributions allows MLE statistics to more efficiently 
provide estimates for the mean and standard deviation 
of estimate for the first component, and provides higher 
confidence in determining the true assay signal.
Malaria seroprevalence estimates for the Haiti serosur-
vey were similar if using different sample types (serum 
or DBS elution) or serology assay protocols (standard 
or OneStep). However, the estimate for PfAMA1 sero-
prevalence as generated by the OneStep protocol with 
serum samples (and the FMM approach) was notably 
lower than the three other experimental conditions. As 
DBS and serum samples were run in parallel, and the 
same bead couplings used throughout the study, the 
simple explanation for the dramatic difference in these 
estimates is that the modeled mean and variance of the 
first component of the OneStep sera data are markedly 
higher when compared to the other three FMM plots for 
PfAMA1. Due to these higher MLE outputs, the MFI-
bg seropositivity threshold (mean + 3SD) was calculated 
to be much higher, and thus, some samples even with a 
high assay signal were not considered to have a MFI-bg 
signal “positive” for IgG against PfAMA1. This shows the 
susceptibility of forcing the mixture model to define two 
components, and comparison of seroestimates and cutoff 
determination schemes with various sample types and 
protocols should be investigated further. Overall, con-
sistency among malaria seroprevalence estimates under 
different MBA conditions would indicate these estimates 
are accurate approximations of the true point prevalence.
Conclusion
When compared to a standard MBA protocol, the 
OneStep serology protocol with samples and reagents 
incubated simultaneously overnight generated compara-
ble estimates of overall seroprevalence for most antigens 
tested in a Haitian malaria survey, and may offer an effi-
cient and flexible approach to large-scale serosurveillance 
studies. As malaria serosurveys become larger and more 
widely employed, options for the timely collection of lab-
oratory data will be needed to allow a fast transition from 
sample collection to analyses.
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